Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced ...

Pembrolizumab (Keytruda, Merck) has picked up another indication — this time for the first-line treatment of unresectable ...

For patients with early-stage triple-negative breast cancer, neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced long-term overall survival (OS) data ...

Notably, patients benefited from pembrolizumab regardless of whether they achieved a pathologic complete response (pCR), ...

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

In head-to-head clinical trial, Chinese firm Akeso’s ivonescimab beat top-selling drug pembrolizumab sold as Keytruda by Merck. Ivonescimab reduced risk of tumour progression by 49%.

The recent ESMO 2024 data highlighted significant advancements in immunotherapy. Check out the results from Merck, BMY, ...

The pembrolizumab group did experience more grade 3 or higher ... Funding for the study was provided by Merck Sharp & Dohme. Van Gorp reported various relationships with AbbVie, AstraZeneca, Amgen, ...

"Neoadjuvant pembrolizumab with chemotherapy followed ... KEYNOTE-522 was supported by Merck Sharp & Dohme. Schmid disclosed relationships with AstraZeneca, Daiichi Sankyo, Gilead, Merck, Novartis ...

At 10 years, more than one-third (34.0%) of patients with advanced melanoma were alive after treatment with KEYTRUDA, compared to 23.6% of patients treated with ipilimumab RAHWAY, N.J., September 15, ...